(Q37250634)

19 August 2017

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. (English)

1 reference

19 August 2017

0 references

13

Jody Clements

0 references

Sarah Edkins

4

Sarah Edkins

1 reference

19 August 2017

43

Sara Widaa

0 references

Sarah O'Meara

6

Sarah O'Meara

0 references

Andy Jenkinson

Andy Jenkinson

23

0 references

Kristian Gray

Kristian Gray

17

0 references

Andrew D Yates

Andy Yates

44

0 references

David Richardson

David Richardson

32

0 references

Christopher I. Hunter

Chris Hunter

22

0 references

William Reinhold

William Reinhold

45

0 references

P. Andrew Futreal

48

P Andrew Futreal

1 reference

19 August 2017

31

Keiran Raine

1 reference

19 August 2017

27

Andrew Menzies

1 reference

19 August 2017

38

Jon Teague

1 reference

19 August 2017

47

Michael R Stratton

1 reference

19 August 2017

49

Richard Wooster

1 reference

19 August 2017

24

David Jones

1 reference

19 August 2017

2

Helen Davies

1 reference

19 August 2017

Ogechi N Ikediobi

1

1 reference

19 August 2017

Graham Bignell

3

1 reference

19 August 2017

Claire Stevens

5

1 reference

19 August 2017

Thomas Santarius

7

1 reference

19 August 2017

Tim Avis

8

1 reference

19 August 2017

Syd Barthorpe

9

1 reference

19 August 2017

Lisa Brackenbury

10

1 reference

19 August 2017

Gemma Buck

11

1 reference

19 August 2017

Adam Butler

12

1 reference

19 August 2017

Jennifer Cole

14

1 reference

19 August 2017

Ed Dicks

15

1 reference

19 August 2017

Simon Forbes

16

1 reference

19 August 2017

Kelly Halliday

18

1 reference

19 August 2017

Rachel Harrison

19

1 reference

19 August 2017

Katy Hills

20

1 reference

19 August 2017

Jonathan Hinton

21

1 reference

19 August 2017

Vivienne Kosmidou

25

1 reference

19 August 2017

Richard Lugg

26

1 reference

19 August 2017

Tatiana Mironenko

28

1 reference

19 August 2017

Adrian Parker

29

1 reference

19 August 2017

Janet Perry

30

1 reference

19 August 2017

Rebecca Shepherd

33

1 reference

19 August 2017

Alex Small

34

1 reference

19 August 2017

Raffaella Smith

35

1 reference

19 August 2017

Helen Solomon

36

1 reference

19 August 2017

Philip Stephens

37

1 reference

19 August 2017

Calli Tofts

39

1 reference

19 August 2017

Jennifer Varian

40

1 reference

19 August 2017

Tony Webb

41

1 reference

19 August 2017

Sofie West

42

1 reference

19 August 2017

John N Weinstein

46

1 reference

19 August 2017

6 November 2006

1 reference

Molecular Cancer Therapeutics

19 August 2017

1 reference

19 August 2017

5

1 reference

19 August 2017

2606-2612

1 reference

19 August 2017

11

1 reference

describes a project that uses

19 August 2017

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705832

Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705832

BRAF mutation predicts sensitivity to MEK inhibition

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705832

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705832

Phosphoinositide 3-kinases as drug targets in cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705832

Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705832

6 September 2017

Targeted cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705832

Lung cancer: intragenic ERBB2 kinase mutations in tumours

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705832

Targeting the p53-MDM2 interaction to treat cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705832

A census of human cancer genes

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705832

High-resolution analysis of DNA copy number using oligonucleotide microarrays

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705832

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705832

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705832

Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705832

Mutations of the BRAF gene in human cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705832

A gene expression database for the molecular pharmacology of cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705832

Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705832

Spotlight on molecular profiling: "Integromic" analysis of the NCI-60 cancer cell lines.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705832

Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705832

Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705832

Identification of inhibitors of the kinase activity of oncogenic V600E BRAF in an enzyme cascade high-throughput screen.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705832

Somatic mutations of the protein kinase gene family in human lung cancer.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705832

Update on NCI in vitro drug screen utilities.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705832

Karyotypic complexity of the NCI-60 drug-screening panel.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705832

An information-intensive approach to the molecular pharmacology of cancer.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705832

The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705832

Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705832

Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705832

Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705832

Neural computing in cancer drug development: predicting mechanism of action

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705832

Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705832

Integromic analysis of the NCI-60 cancer cell lines

3 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17088437

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17088437

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17088437

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/1535-7163.MCT-06-0433

1 reference

19 August 2017

1 reference

19 August 2017

1 reference